HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
about
HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis.Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens.Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer.Clinical significance of quantitative HER2 gene amplification as related to its predictive value in breast cancer patients in neoadjuvant setting.Relationship between gene status and selected potential biological features related to trastuzumab resistance and its influence on survival of breast cancer patients undergoing trastuzumab adjuvant treatment
P2860
HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
HER2/CEP17 ratio and HER2 immu ...... tive metastatic breast cancer.
@en
HER2/CEP17 ratio and HER2 immu ...... tive metastatic breast cancer.
@nl
type
label
HER2/CEP17 ratio and HER2 immu ...... tive metastatic breast cancer.
@en
HER2/CEP17 ratio and HER2 immu ...... tive metastatic breast cancer.
@nl
prefLabel
HER2/CEP17 ratio and HER2 immu ...... tive metastatic breast cancer.
@en
HER2/CEP17 ratio and HER2 immu ...... tive metastatic breast cancer.
@nl
P2093
P2860
P1476
HER2/CEP17 ratio and HER2 immu ...... tive metastatic breast cancer.
@en
P2093
Do-Youn Oh
Hye-Suk Han
In Ae Park
Jee Hyun Kim
Jin-Soo Kim
Kyung-Hun Lee
Sae-Won Han
Seock-Ah Im
Tae-Yong Kim
Tae-You Kim
P2860
P2888
P304
P356
10.1007/S00280-013-2174-1
P50
P577
2013-05-15T00:00:00Z